POM-V Prescription Required Companion Animal

Amodip 1.25 mg Chewable Tablets for Cats

Active ingredient: Amlodipine

Form

Chewable

Species

Cats

Manufacturer

Ceva Sante Animale

VMD MA No.

14966/5022

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Amlodipine

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Amodip 1.25 mg Chewable Tablets for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

After 14 days of treatment, the dose may subsequently be doubled or increased up to
0.5 mg/kg once daily if adequate clinical response has not been achieved (e.g.
systolic blood pressure remaining over 150 mmHg or a decrease of less than 15 %
from the pre-treatment measurement).
Weight of cat (kg)Starting dose (number of tablets)2.5 - 5.0 0.55.1 - 10.0 110.1 and above2
The tablets can be given directly to the animals or administered with a small quantity
of food.

Do not use in the case of cardiogenic shock and severe aortic stenosis.
Do not use in cases of severe hepatic failure.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cats:
Very common
(>1 animal / 10 animals
treated):
Emesis
, Gingival hyperplasia
Enlarged lymph node (localised)
2,3
Common
(1 to 10 animals / 100 animals
treated):
Diarrhoea
Lethargy, Dehydration, Anorexia
1
Mild and transient
At the dose of 0.25 mg/kg, observed in healthy young adult cats but not in the
clinical trial with older hypertensive cats. This does not usually require stopping the
treatment.
Submandibular
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

The primary cause and/or co-morbidities of hypertension, such as hyperthyroidism,
chronic kidney disease and diabetes, should be identified and treated.
In cats situational hypertension (also called white coat hypertension) occurs as a
consequence of the in-clinic measurement process in an otherwise normotensive
animal. In case of high stress levels measurement of systolic blood pressure may
lead to incorrect diagnosis of hypertension. It is recommended that stable
hypertension is confirmed by repeated measurement of systolic blood pressure on
different days before commencing therapy.
Continued administration of the product over an extended period of time should be in
accordance with an ongoing benefit/risk evaluation, performed by the prescribing
veterinarian that includes measurement of systolic blood pressure routinely during
treatment (e.g. every 6 to 8 weeks).

Special precautions for safe use in the target species:
Special caution is required in patients with hepatic disease as amlodipine is highly
metabolised by the liver. As no studies have been conducted in animals with liver
disease, use of the product in these animals should be based on a benefit-risk
assessment by the attending veterinarian.
Administration of amlodipine may sometimes result in a decrease in serum potassium
and chloride levels. Monitoring of those levels is recommended during treatment.
Older cats with hypertension and chronic kidney disease (CKD) may also suffer from
hypokalaemia as a result of their underlying disease.
The safety of amlodipine has not been established in cats weighing less than 2.5 kg.
Safety has not been tested in cats with cardiac failure. Use in these cases should be
based on a benefit risk assessment by the veterinarian.
The chewable tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of the animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This product may decrease blood pressure. In order to reduce the risk of accidental
ingestion by children, do not take the tablets out of blisters until ready to administer to
the animal. Return part-used tablets into the blister and carton. In case of accidental
ingestion, seek medical advice immediately and show the package leaflet or the label
to the physician.
People with known hypersensitivity to amlodipine should avoid contact with the
veterinary medicinal product. Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Not applicable.

Concomitant use of amlodipine with other agents that may reduce blood pressure
may cause hypotension. These agents include: diuretics, beta-blockers, other
calcium channel blockers, inhibitors of the renin angiotensin aldosterone system
(renin inhibitors, angiotensin II receptor blockers, angiotensin converting enzyme
inhibitors (ACEI), and aldosterone antagonists), other vasodilators and alpha-2
agonists. It is advised to measure blood pressure before administering amlodipine
with these agents and to ensure cats are adequately hydrated.
However, in clinical cases of feline hypertension, no evidence of hypotension
occurring as a result of combining amlodipine with the ACEI benazepril was
observed.
Concomitant use of amlodipine with negative chronotropes and inotropes (such as
beta-blockers, cardioselective calcium channel blockers and antifungal azoles (e.g
itraconazole) may reduce force and rate of contraction of the heart muscle.
Particular attention must be paid before administering amlodipine with these drugs in
cats with ventricular dysfunction.
The safety of concomitant use of amlodipine and the anti-emetic agents dolasetron
and ondansetron has not been evaluated in cats.

Do not store above 30 °C.
Any unused half tablets should be returned to the blister pack.

The tablets can be given directly to the animals or administered with a small quantity
of food.
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
Reversible hypotension may occur in cases of accidental overdose. Therapy is
symptomatic.
After administration of 0.75 mg/kg and 1.25 mg/kg once daily for 6 months to healthy
young adult cats, hyperplastic gingivitis, reactive lymphoid hyperplasia in mandibular
lymph nodes, and increased Leydig cell vacuolisation and hyperplasia were seen. At
the same dose levels plasma potassium and chloride levels were decreased and an
increase in urinary volume associated with decreased urinary specific gravity was
observed. These effects are unlikely to be observed under clinical conditions with
short term accidental overdosing.
In a small two-week tolerance study of healthy cats (n=4), doses between 1.75 mg/kg
and 2.5 mg/kg were administered, and mortality (n=1) and severe morbidity (n=1)
occurred.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.